| Literature DB >> 30112813 |
Janne Kananen1,2, Timo Tuovinen1,2, Hanna Ansakorpi3,4, Seppo Rytky5, Heta Helakari1,2, Niko Huotari1,2, Lauri Raitamaa1,2, Ville Raatikainen1,2, Aleksi Rasila1,2, Viola Borchardt1,2, Vesa Korhonen1,2, Pierre LeVan6, Maiken Nedergaard7,8, Vesa Kiviniemi1,2.
Abstract
INTRODUCTION: Functional magnetic resonance imaging (fMRI) combined with simultaneous electroencephalography (EEG-fMRI) has become a major tool in mapping epilepsy sources. In the absence of detectable epileptiform activity, the resting state fMRI may still detect changes in the blood oxygen level-dependent signal, suggesting intrinsic alterations in the underlying brain physiology.Entities:
Keywords: zzm321990MREGzzm321990; zzm321990fMRIzzm321990; brain physiology; coefficient of variation; epilepsy; multimodal imaging
Mesh:
Year: 2018 PMID: 30112813 PMCID: PMC6160661 DOI: 10.1002/brb3.1090
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Clinical characteristics of 10 recruited epilepsy patients
| DRE patient | Duration of epilepsy, years | Seizure type | Previous neurophysiological findings | Antiepileptic drugs |
|---|---|---|---|---|
| 1 | 8 | Focal with impaired awareness |
MRI: Previously normal. Now, right amygdala/temporal cortex unspecified pathology | Carbamazepine 800 mg, Pregabalin 300 mg |
| 2 | 10 | Focal with impaired awareness |
MRI: Mild right hippocampal sclerosis | Lamotrigine 550 mg, Topiramate 200 mg |
| 3 | 19 | Focal to bilateral tonic–clonic |
MRI: Normal |
Lacosamide 200 mg, Lamotrigine 175 mg, |
| 4 | 4 | Focal with impaired awareness |
MRI: Normal, possible FCD in left temporal middle gyrus |
Lacosamide 150 mg |
| 5 | 6 | Focal to bilateral tonic–clonic |
MRI: Normal |
Levetiracetam 2,500 mg, |
| 6 | 13 | Focal to bilateral tonic–clonic |
MRI: Normal |
Lamotrigine 100 mg, |
| 7 | 12 | Focal to bilateral tonic–clonic |
MRI: Normal |
Valproic acid 900 mg, |
| 8 | 11 | Focal with impaired awareness |
MRI: Normal |
Oxcarbazepine 1,200 mg, |
| 9 | 12 | Focal with impaired awareness |
MRI: Normal |
Topiramate 100 mg, |
| 10 | 7 | Focal with impaired awareness |
MRI: Normal |
Levetiracetam 2,000 mg, |
DRE: drug‐resistant epilepsy; MRI, magnetic resonance imaging; EEG: electroencephalography.
Figure 1Calculation and analysis of CV. (a) Example randomly selected patient and control subject for CV voxel‐wise calculation with an example of signal and it is mean and SD values of single voxel. After voxel‐wise calculation of CV data were normalized to standard MNI152 space and the whole‐brain CV map was produced. (b) Threshold image was derived from HC data by calculating mean and SD within the group. The SD value was multiplied by 3 and added to the HC mean to obtain the threshold image. (c) The previously calculated threshold image from HC group was subtracted from each patient measurement for individual map of CV. Values over the threshold were binarized, and then, the overlapping areas in both measurements were calculated. *,** indicates the same image in the calculation process
Figure 2Individual findings after thresholding consecutively. Individual threshold maps of overlapping areas in repeated scanning for every patient separately in patient's own anatomy in MNI space. Interesting ROIs shown. Every patient has different areas influenced constantly. Areas of CV that corresponded clinical symptoms from patient records are marked accordingly to finding type
Figure 6Additional analyze methods between the groups. (a) Template‐based analysis, in which each template voxels CV values are shown. There are statistically significant differences between HC and DRE patients in GM and WM in first scan (p < 0.05). In the second scan, the significant difference in GM is more pronounced (p < 0.01) than WM and CSF (p < 0.05). (b) Interesting voxels left in HC and patient group with μ+2σ and μ+3σ thresholds. (c) Global signal μ, σ, and CV values between groups. There was significant difference (p < 0.05) in σ and CV values between HC and second patient scan, but also between first scan and second scan. DER: drug‐resistant epilepsy
Figure 3Brainstem alterations on an individual level. (a) Individual threshold CV maps of brainstem alterations in repeated scanning in yellow. (b) The overlapping statistical significant differences between the groups with p‐value <0.05 in two scans. Group differences are also displayed in axial view. (c) The anatomical map of brainstem respiration centers. The labeling of anatomical areas was performed in style of the “Fundamentals of Human Physiology,” 4th edition, author: Lauralee Sherwood, Chapter 2, page 374, Fig 12–25
Figure 4Group level differences. Statistically significant voxels and their p‐values in full band fMRI signal between the HC and DRE patients. (a) On the top panel are shown significant differences in the first scan (p < 0.05). (b) On the lower panel are shown significant differences of second scan (p < 0.01). DRE: drug‐resistant epilepsy
Figure 5Group level differences in different sub bands. Statistically significant voxels and their p‐values in filtered fMRI time series between the HC and DRE patients. (a) In the first scan, there were significant differences (p < 0.05) only in respiratory (0.12–0.4 Hz) band. (b) In the second scan, both the low frequency and the respiratory band were significantly different (p < 0.01), and the cardiac band was significantly different (p < 0.05). DRE: drug‐resistant epilepsy
Global signal and motion parameters between groups
| Signal | HC | DRE Scan 1 | DRE Scan 2 |
|
|
|---|---|---|---|---|---|
| Global fMRI: Mean (a.u.) | 2,524.80 ± 108.20 | 2,482.78 ± 106.61 | 2,507.41 ± 105.43 | 0.84 | 0.62 |
| Global fMRI: | 6.04 ± 2.59 | 5.99 ± 2.20 | 11.18 ± 5.44 | 0.45 | 0.014 |
| Global fMRI: CV | 0.0024 ± 0.0010 | 0.0024 ± 0.0009 | 0.0045 ± 0.0022 | 0.55 | 0.21 |
| Motion: Absolute, mean (mm) | 0.94 ± 0.50 | 1.30 ± 0.25 | 0.63 ± 0.22 | 0.14 | 0.21 |
| Motion: Relative, mean (mm) | 0.054 ± 0.019 | 0.055 ± 0.011 | 0.048 ± 0.010 | 0.91 | 0.34 |
| Motion: Absolute, CV | 0.68 ± 0.090 | 0.73 ± 0.085 | 0.71 ± 0.061 | 0.14 | 0.68 |
| Motion: Relative, CV | 0.77 ± 0.15 | 0.90 ± 0.19 | 0.66 ± 0.10 | 0.14 | 0.10 |
DRE: drug‐resistant epilepsy.
Figure 7Motion and physiological parameters. (a) Absolute and relative motion and their CV values between groups. Only difference is that there is much less absolute motion in second scan (p = 0.00044). (b) Differences in both respiratory and cardiorespiratory signals between groups were absent
Cardiorespiratory signal characteristics between groups
| Signal | HC | DRE combined scans |
|
|---|---|---|---|
| Cardio: frequency | 68.11 ± 8.14 | 70.29 ± 9.90 | 0.70 |
| Cardio: CV | 0.32 ± 0.014 | 0.32 ± 0.066 | 0.93 |
| Respiratory: frequency | 13.31 ± 3.16 | 14.92 ± 3.75 | 0.74 |
| Respiratory: CV | 0.84 ± 0.10 | 0.91 ± 0.16 | 0.50 |
| Cardio, HC2nd: frequency | 71.46 ± 10.26 | 0.80 | |
| Cardio, HC2nd: CV | 0.30 ± 0.030 | 0.47 | |
| Respiratory, HC2nd: Frequency | 16.56 ± 3.08 | 0.32 | |
| Respiratory, HC2nd: CV | 0.81 ± 0.20 | 0.45 |
DRE: drug‐resistant epilepsy.